The DEA Just Said Delta-8 and HHC Are Still Illegal. The White House Agrees. Target Didn’t Get the Memo.

On Wednesday, the Drug Enforcement Administration restated something it has been saying for years — but saying with renewed clarity, and at a moment when it is starting to matter much more.

“To clarify further,” the agency wrote, “tetrahydrocannabinols produced through chemical conversion, even when hemp-derived, are considered synthetically produced for purposes of the Controlled Substances Act.”

That sentence is a legal hand grenade for an industry that has spent the better part of six years convincing itself otherwise. Delta-8 THC, delta-10, HHC, and a handful of other novel cannabinoids have all been commercially viable largely because sellers have argued they’re legitimate hemp derivatives under the 2018 Farm Bill — that since the raw material started as federally legal hemp, the finished product should be too. The DEA’s latest statement makes clear it does not agree, and never did.

The timing is not incidental. Within hours of the DEA’s restatement, reporting out of Washington confirmed the Trump administration is treating intoxicating hemp as a priority target in its 2026 National Drug Control Strategy — the first such strategy of the current administration. The document, produced by the Office of National Drug Control Policy (ONDCP), signals a crackdown on synthetic hemp products with high THC concentrations. The White House has now effectively aligned with the DEA’s longstanding position: the Farm Bill’s 0.3 percent delta-9 THC threshold does not immunize a product whose intoxicating punch was chemically manufactured after harvest.

What “Chemical Conversion” Actually Means

The distinction the DEA is drawing has been legally contested for years, but the agency’s reasoning is fairly straightforward when spelled out. Hemp is federally legal because it contains less than 0.3 percent delta-9 THC by dry weight. The Farm Bill drew that line specifically around one cannabinoid — delta-9 — and did not legalize cannabis in general.

The hemp industry responded creatively. Delta-8 THC is a cannabinoid that exists in trace amounts in the natural plant but can be produced in bulk by chemically converting CBD — another hemp-derived compound that is abundantly available — through an isomerization process using acids and solvents. The resulting product is psychoactive. It gets people high. And it does so via a cannabinoid that never appears in high concentrations in a natural hemp plant.

The DEA’s argument is that the moment you run CBD through a chemical reaction to produce a different compound, you’ve left the Farm Bill’s protection behind. The raw material’s origin is irrelevant; what matters is the manufacturing process. Under the Controlled Substances Act, synthetically derived tetrahydrocannabinols remain Schedule I — full stop.

The same logic applies to HHC (hexahydrocannabinol), a hydrogenated form of THC; to THCO-acetate, which has no natural analogue in the plant whatsoever; and arguably to many high-concentration THCA products, where the naturally occurring acid form of THC is effectively a delivery mechanism for delta-9 once it’s heated.

The White House Closes the Loop

The 2026 National Drug Control Strategy appears to be the policy architecture that would give enforcement teeth to the DEA’s legal interpretation. Previous administrations — including Trump’s first term — largely left the intoxicating hemp gray market alone. The industry grew to enormous scale in that window. Estimates of annual retail sales for hemp-derived THC products run into the billions of dollars. Products that would require a state cannabis license to sell legally are available in gas stations and convenience stores in states that have no cannabis program at all.

That period of regulatory tolerance now appears to be ending. ONDCP’s inclusion of synthetic hemp in its national drug control framework is meaningful because it signals coordination across federal agencies — not just the DEA restating old positions in isolation, but the executive branch signaling it wants those positions enforced.

For operators in the delta-8 and HHC space, the calculus has changed. This is no longer a matter of waiting out a regulatory gap. The question is whether enforcement actually follows the rhetoric — which, to be fair, it hasn’t consistently done before.

Target’s Curious Bet

Against this backdrop, news that Target is expanding hemp THC drinks into more than 300 stores across Florida, Texas, and Illinois is either extremely ill-timed or quietly significant.

The report, published Wednesday, frames the move as a bet placed roughly six months before what analysts have been calling a probable federal ban on intoxicating hemp-derived beverages. On its face, that sounds like a retailer stumbling into a regulatory minefield. But the alternative reading — that a company with Target’s legal and compliance infrastructure made this move knowing something the rest of the market doesn’t — is at least worth considering.

Beverages are, in some ways, a different category than the vape cartridges and gummies that have drawn the most regulatory scrutiny. Hemp THC drinks are produced through processes that may differ legally from classic isomerization routes, depending on the specific compounds and formulations involved. Some beverage makers argue their products sit in a different part of the regulatory spectrum.

Whether that argument holds under the DEA’s current framework is untested. But Target moving into this space at this specific moment is a data point that industry observers will be watching closely.

What Operators Should Be Doing Right Now

The honest answer is that anyone selling delta-8, HHC, or similarly synthesized cannabinoids should have legal counsel reviewing their exposure with urgency. The DEA’s restatement combined with White House priority signaling creates a threat environment that is materially different from even six months ago.

State-licensed cannabis operators, meanwhile, have every incentive to push for vigorous enforcement. Unlicensed hemp-derived THC products undercut their market, avoid the taxes and testing requirements they’re subject to, and carry risks for consumers who have no way to verify what’s in a product sold at a truck stop. The cannabis industry’s most established players have been lobbying for exactly the kind of federal intervention that now appears to be coming.

The Farm Bill gray market was always a bet that federal inaction would persist indefinitely. The DEA’s statement this week is a reminder that federal law never changed — only federal will.

Morgan Ellis covers hemp-derived THC, Farm Bill policy, and federal cannabis enforcement for CannabisInquirer.com.